- Home
- ZVRA
as 11-21-2024 3:42pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | CELEBRATION |
| Market Cap: | 473.6M | IPO Year: | 2015 |
| Target Price: | $21.20 | AVG Volume (30 days): | 669.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.20 - $9.27 | Next Earning Date: | 11-12-2024 |
| Revenue: | $24,489,000 | Revenue Growth: | 47.85% |
| Revenue Growth (this year): | -13.04% | Revenue Growth (next year): | 318.48% |
Stock Insider Trading Activity of Zevra Therapeutics Inc. (ZVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watton Corey Michael | ZVRA | Director | Oct 11 '24 | Buy | $7.92 | 500 | $3,957.65 | 1,500 |
Latest Zevra Therapeutics Inc. News
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report
Simply Wall St.
7 days ago
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
9 days ago
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
Zacks
9 days ago
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
9 days ago
Zevra Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
9 days ago
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
Zacks
10 days ago
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
10 days ago
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
Compare ZVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.